US FDA Again Looks Outside Generic Drugs Office For New Director
Executive Summary
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.
You may also be interested in...
Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says
Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’
FDA Seeks New Generics Chief As Choe Moves On
The US Food and Drug Administration has begun searching for a new director for its Office of Generic Drugs, after announcing that Sally Choe will leave the agency in early October.
US FDA's 'Great' Generic Approval Engine Can Be Better, New OGD Director Says
In interview with the Pink Sheet, Sally Choe expresses doubts that setting goals for approval totals is productive, saying the current workflow looks fine.